- 10:19 AM Buy HOEC on all declines: Mitesh Thacker
- 10:13 AM Book profit in Sesa Goa at Rs 340: Thacker
- 10:04 AM SEBI bars Pyramid Saimira for 7yrs in IPO irregula...
- 09:58 AM Pantaloon Retail may slip to Rs 265: Thacker
- 09:56 AM Sensex flat in early trade; telecom, realty slip i...
- 09:55 AM Mkt may trade sideways on quiet global cues: Udaya...
- 09:54 AM State Trading Corporation can test Rs 425: M Thack...
- 09:51 AM Buy ITI with stoploss of Rs 45.50: M Thacker
- 09:49 AM Nifty has resistance at 4945-4950: Reliance Sec
- 09:49 AM Trade long if Nifty holds 4860 levels: Karvy



Broking house, ENAM Securities has maintained neutral rating on Glenmark Pharma.
ENAM Securities report on Glenmark Pharma:
|
RSS feed for news about this stock Click here |
Robust US generics sales drive growth:
Glenmark’s reported numbers for Q4FY07 were above expectations, with net sales at Rs 2.7bn (up 65% YoY), EBIDTA at Rs 907mn (up 179% YoY) and PAT at Rs 626mn (up 150% YoY). EBIDTA margin at 33% was up by over 13%. Consolidated Q4 sales were Rs 3.4bn, with EBIDTA at Rs 1bn and PAT at Rs 632mn. Consolidated sales for FY07 were USD 281mn (up 64%) and PAT was USD 69mn (up 255%).
Q4FY07 Highlights:
The highlight of the quarter was a strong performance in the US generics market, where Glenmark registered sales of USD 18.2mn (up 149% YoY). Glenmark and its partners have 13 products in the US market (with ~25% market share in major products); they also have another 36 products awaiting FDA approval. The company recently filed a Para IV ANDA for ezetimibe (Schering’s Zetia), which has annual sales of USD 1.5bn.
Branded formulation exports to semi-regulated markets were up 68% YoY to Rs 454mn. Glenmark received 147 registrations and filed for another 62 in various export markets, during the quarter. With the commencement of operations in Turkmenistan and Cameroon during Q4, it has added nine new markets during FY07 and now has operations in 80 countries.
Glenmark’s Latam subsidiaries (Glenmark Farmaceutica Ltda, Brazil and Servycal S.A., Argentina) posted revenues of USD 15.3mn in Q4FY07 (up 73% YoY). In Q4, it filed four new dossiers with ANVISA, Brazil and three with ANMAT, Argentina, taking total filings across Latam to 40.
At CMP (Rs 677), it trades at 17.8x FY08E EPS of Rs 38 and 14.9x FY09E EPS of Rs 45. While these are not demanding valuations, they factor in large upsides from milestones, which should be assigned far higher risk weightages. We maintain our sector Neutral rating.
|
Stock Advice
|
|
|


Today's Special Column
with Ashok Gulati
International Food Policy Research Institute , Director in Asia


-
Most Read
-
Most Viewed
- 10 companies that MF managers love
- 10 Companies that FIIs love
- Experts on stocks and sectors to pick/avoid now

- Sensex may drift down to 12500, -ve on RIL: Shankar Sharma

- IPO scam: SEBI bars Pyramid Saimira for 7 years

- Ganeshaspeaks: Market prediction for Nov 11
- What are Ashish Chugh's hidden gems for Nov?

- Mitesh Thacker's top picks for today's trade
- SEBI bars Pyramid Saimira for 7yrs in IPO irregularity case
Source: Moneycontrol.com
- Pantaloon Retail may slip to Rs 265: Thacker
Source: CNBC-TV18
- Sensex flat in early trade; telecom, realty slip in red
Source: Moneycontrol.com
- Mkt to trade sideways on quiet global cues
Source: CNBC-TV18
- Kochi port urges Govt to lift palm oil import ban
Source: Business Line
- Punj Lloyd signs JV agreement with Delta Solar
Source: Business Line
- IL&FS renegotiates Maytas Infra debt package with lenders
Source: Business Line
- Neyveli Lignite to set up wind power project
Source: Business Line





















